Formononetin 7-O-(2'',6''-di-O-(E-p-coumaroyl)glucoside)



Compound IDCDAMM00432
Common nameFormononetin 7-O-(2'',6''-di-O-(E-p-coumaroyl)glucoside)
IUPAC name[3,4-dihydroxy-5-[3-(4-hydroxyphenyl)prop-2-enoyloxy]-6-[3-(4-methoxyphenyl)-4-oxochromen-7-yl]oxyoxan-2-yl]methyl 3-(4-hydroxyphenyl)prop-2-enoate
Molecular formulaC40H34O13

Experimental data

Retention time15.31
Adduct[M+H]+
Actual mz723.201
Theoretical mz723.207
Error9.23
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.3033

Identifiers and class information

Inchi keyGSUCRXNVNQIYKV-CZJQLYNQNA-N
SmilesO=C(OCC1OC(OC2=CC=C3C(=O)C(=COC3=C2)C=4C=CC(OC)=CC4)C(OC(=O)C=CC5=CC=C(O)C=C5)C(O)C1O)C=CC6=CC=C(O)C=C6
SuperclassPhenylpropanoids and polyketides
ClassIsoflavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)6
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)17
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)722.701
Computed dipole moment(dipole)5.099
Total solvent accessible surface area (SASA)976.153
Hydrophobic component of SASA (FOSA)210.81
Hydrophilic component of SASA (FISA)269.339
Pie component of the SASA (PISA)496.004
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1955.8
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)14.6
Free energy of solvation of dipole (dip^2/V)0.0132918
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0299133
Globularity descriptor (glob)0.774812
Predicted polarizability in cubic angstroms (QPpolrz)65.938
Predicted hexadecane/gas partition coefficient (QPlogPC16)22.644
Predicted octanol/gas partition coefficient (QPlogPoct)36.9
Predicted water/gas partition coefficient (QPlogPw)23.763
Predicted octanol/water partition coefficient (QPlogPo/w)3.789
Predicted aqueous solubility (QPlogS)-5.687
Conformation-independent predicted aqueous solubility (CIQPlogS)-9.53
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-7.541
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)27.654
Predicted brain/blood partition coefficient (QPlogBB)-3.452
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)10.235
Predicted skin permeability, log Kp (QPlogKp)-3.104
PM3 calculated ionization potential (IP(ev))8.785
PM3 calculated electron affinity (EA(eV))0.959
Number of likely metabolic reactions (#metab)5
Prediction of binding to human serum albumin (QPlogKhsa)0.227
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)49.016
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)210.955
Number of nitrogen and oxygen atoms (#NandO)13
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
P43166CA7Carbonic anhydrase VIIT37541SEA
P23280CA6Carbonic anhydrase VIT06569SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P22748CA4Carbonic anhydrase IVT53378SEA
P60568IL2Interleukin-2T61698SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA
P14679TYRTyrosinaseT97035SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
P16152CBR1Carbonyl reductase [NADPH] 1T70518SEA
O43826SLC37A4Glucose-6-phosphate translocaseT47306SEA
P49862KLK7Kallikrein-7T79155SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T06569DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P23280CA6
T06569DI0372Seborrhoeic dermatitis[ICD-11: EA81]P23280CA6
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025